205 related articles for article (PubMed ID: 34138566)
21. Discovery of potent small molecule PROTACs targeting mutant EGFR.
Zhao HY; Yang XY; Lei H; Xi XX; Lu SM; Zhang JJ; Xin M; Zhang SQ
Eur J Med Chem; 2020 Dec; 208():112781. PubMed ID: 32883633
[TBL] [Abstract][Full Text] [Related]
22. Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib.
Radaram B; Pisaneschi F; Rao Y; Yang P; Piwnica-Worms D; Alauddin MM
Eur J Med Chem; 2019 Nov; 182():111571. PubMed ID: 31425908
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
24. Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer.
Huang J; Huang J; Wang N; Wang L; Li L; Wang C; Sun X; Li Y; Huang G; Ma X
Bioorg Chem; 2019 Aug; 89():102994. PubMed ID: 31185393
[TBL] [Abstract][Full Text] [Related]
25. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
26. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
Kong X; Pan P; Sun H; Xia H; Wang X; Li Y; Hou T
J Med Chem; 2019 Dec; 62(24):10927-10954. PubMed ID: 31419130
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a potent dual ALK and EGFR T790M inhibitor.
Jang J; Son JB; To C; Bahcall M; Kim SY; Kang SY; Mushajiang M; Lee Y; Jänne PA; Choi HG; Gray NS
Eur J Med Chem; 2017 Aug; 136():497-510. PubMed ID: 28528303
[TBL] [Abstract][Full Text] [Related]
28. Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression.
Chen J; Zhou Y; Dong X; Liu L; Bai L; McEachern D; Przybranowski S; Yang CY; Stuckey J; Li X; Wen B; Zhao T; Sun S; Sun D; Jiao L; Jing Y; Guo M; Yang D; Wang S
J Med Chem; 2020 Nov; 63(22):13994-14016. PubMed ID: 33185101
[TBL] [Abstract][Full Text] [Related]
29. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
[TBL] [Abstract][Full Text] [Related]
30. Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations.
Cao M; Chen Y; Zhao T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115715. PubMed ID: 33069079
[TBL] [Abstract][Full Text] [Related]
31. Brigatinib for
Ali R; Arshad J; Palacio S; Mudad R
Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
[TBL] [Abstract][Full Text] [Related]
33. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
35. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
Das D; Xie L; Wang J; Shi J; Hong J
Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037
[TBL] [Abstract][Full Text] [Related]
36. Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors.
Xiao Z; Chu C; Zhou L; Zhou Z; Zhang Q; Yang F; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Med Chem; 2020 Oct; 28(19):115669. PubMed ID: 32912435
[TBL] [Abstract][Full Text] [Related]
37. Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants.
Zhu M; Li W; Zhao T; Chen Y; Li T; Wei S; Guo M; Zhai X
Bioorg Med Chem; 2020 Oct; 28(20):115719. PubMed ID: 33069075
[TBL] [Abstract][Full Text] [Related]
38. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
[TBL] [Abstract][Full Text] [Related]
40. Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
Cheng M; Yu X; Lu K; Xie L; Wang L; Meng F; Han X; Chen X; Liu J; Xiong Y; Jin J
J Med Chem; 2020 Feb; 63(3):1216-1232. PubMed ID: 31895569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
